Paliperidone side effects: prolactin, EPS, what to watch for

Paliperidone, marketed as Invega in oral form and as Invega Sustenna (monthly), Invega Trinza (every three months), and Invega Hafyera (every six months) as long-acting injectables, is the active metabolite of risperidone. In other words: when you take risperidone, your liver converts much of it into paliperidone. Giving paliperidone directly skips that step and gives more predictable blood levels with somewhat less variability across patients.

The clinical implication is that paliperidone's side effect profile largely mirrors risperidone's — but with its own characteristic shape worth understanding.

Hyperprolactinemia: the most distinctive side effect

Paliperidone has one of the strongest effects on prolactin of any modern antipsychotic, comparable to or slightly greater than risperidone. The mechanism is straightforward — dopamine normally suppresses prolactin release from the pituitary, and dopamine blockade releases that brake.

Symptoms of elevated prolactin can include:

• Loss of menstrual periods or irregular periods in women
• Galactorrhea (milk production from the breasts) in men or women
• Reduced libido
• Erectile dysfunction in men
• Breast enlargement (gynecomastia) in men
• Long-term concerns about bone density with persistent elevation

Many patients have elevated prolactin levels without any noticeable symptoms; some have substantial symptoms with only modest elevations. See our broader discussion at hyperprolactinemia and antipsychotics.

Mitigation strategies

• Lowering the dose, when symptoms allow
• Switching to a more prolactin-sparing agent (aripiprazole, brexpiprazole, cariprazine, quetiapine, lurasidone)
• Adding low-dose aripiprazole alongside paliperidone — there is evidence this can lower prolactin without compromising symptom control
• Hormonal evaluation if symptoms persist

Extrapyramidal symptoms (EPS)

Paliperidone is firmly dose-dependent for EPS. At lower doses (3 mg) the rate is comparable to placebo in trials; at higher doses (9–12 mg) it rises noticeably. EPS includes:

• Akathisia — restlessness and an urge to move
• Parkinsonism — tremor, stiffness, slowed movement, masked facial expression
• Dystonia — sustained muscle contractions, particularly of the neck, jaw, or eyes; usually early
• Tardive dyskinesia — involuntary movements, particularly of the face and tongue, usually after long-term use

See our EPS overview and tardive dyskinesia explainer for more detail.

Weight and metabolic effects

Paliperidone causes more weight gain than aripiprazole or ziprasidone but less than olanzapine or clozapine. Average gain in the first year is typically in the 3–6 kg range, though individual variation is large. Effects on lipids and glucose are modest but warrant monitoring under the standard ADA/APA consensus framework.

Practical strategies — earlier weighing, sugar-sweetened drink reduction, daily movement, possibly metformin — apply here as for any second-generation antipsychotic. See our weight gain management guide.

Sedation

Paliperidone is moderately sedating, though usually less than olanzapine or quetiapine. The extended-release oral formulation (Invega) often produces a smoother experience than immediate-release risperidone because of its sustained delivery system. Many patients take it in the morning to minimise sleep disruption.

Orthostatic hypotension

Less common than with quetiapine or clozapine but real, particularly during dose initiation. Standing up slowly, hydration, and avoiding alcohol help.

QT effects

Paliperidone has modest QT-prolonging effects, smaller than ziprasidone but not absent. Caution with combinations of QT-prolonging medications. Baseline ECG is reasonable for patients with cardiac risk factors. See QT prolongation.

The long-acting injectable side

Invega Sustenna, Trinza, and Hafyera are paliperidone palmitate suspensions given by intramuscular injection at intervals of one, three, or six months respectively. They eliminate daily pill-taking and reduce relapse rates compared with oral medication, as documented in NIMH-funded studies. They share oral paliperidone's side effect profile, plus:

• Injection site reactions — pain, swelling, induration; usually settles within days
• Once a side effect is established, it can persist longer because the drug clears slowly. This makes baseline tolerance to oral paliperidone particularly important.

Rare but serious

• Neuroleptic malignant syndrome — rare, life-threatening
• Tardive dyskinesia — risk increases with cumulative exposure
• Hyperglycemia and new-onset diabetes — uncommon but warrants monitoring
• Boxed warning — increased mortality in elderly patients with dementia-related psychosis

When to call the prescriber

• Loss of menstrual periods, breast changes, or sexual side effects
• Persistent restlessness or inability to sit still
• New tremor, stiffness, or unusual facial movements
• Significant weight gain (>5% of starting body weight in three months)
• Any thoughts that the medication is no longer working — better to discuss than to silently stop

Switching considerations

If paliperidone is poorly tolerated, common alternatives include:

• Aripiprazole — much less prolactin elevation, lighter on weight, but more akathisia and insomnia
• Lurasidone — less prolactin, less weight, but food requirement
• Cariprazine — partial agonist, prolactin-sparing, long half-life
• Olanzapine — heavier on metabolics but no prolactin issue

If a long-acting injectable is the goal but paliperidone does not fit, aripiprazole monohydrate (Abilify Maintena) or aripiprazole lauroxil (Aristada) offer the LAI advantage with a different side effect profile.

The bigger picture

Paliperidone is a workhorse antipsychotic with strong evidence, predictable kinetics, and excellent long-acting options. It is also a medication that demands honest conversation about prolactin and movement effects — particularly because the long-acting forms make it harder to step away quickly if problems develop. The right candidate is someone who has tolerated risperidone or paliperidone in oral form, who values a long dosing interval, and whose clinical context calls for the reliable D2 blockade that this drug class provides.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.